<?xml version="1.0" encoding="UTF-8" standalone="no"?><document id="DrugDDI.d125" origId="Paclitaxel"><sentence id="DrugDDI.d125.s0" origId="s0" text="In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin)."><entity charOffset="45-50" id="DrugDDI.d125.s0.e0" origId="s0.p3" text="TAXOL" type="drug"/><entity charOffset="71-80" id="DrugDDI.d125.s0.e1" origId="s0.p9" text="cisplatin" type="drug"/><entity charOffset="169-174" id="DrugDDI.d125.s0.e2" origId="s0.p22" text="TAXOL" type="drug"/><entity charOffset="191-200" id="DrugDDI.d125.s0.e3" origId="s0.p25" text="cisplatin" type="drug"/><entity charOffset="239-244" id="DrugDDI.d125.s0.e4" origId="s0.p30" text="TAXOL" type="drug"/><entity charOffset="252-261" id="DrugDDI.d125.s0.e5" origId="s0.p31" text="cisplatin" type="drug"/><pair e1="DrugDDI.d125.s0.e0" e2="DrugDDI.d125.s0.e1" id="DrugDDI.d125.s0.p0" interaction="false"/><pair e1="DrugDDI.d125.s0.e0" e2="DrugDDI.d125.s0.e2" id="DrugDDI.d125.s0.p1" interaction="false"/><pair e1="DrugDDI.d125.s0.e0" e2="DrugDDI.d125.s0.e3" id="DrugDDI.d125.s0.p2" interaction="false"/><pair e1="DrugDDI.d125.s0.e0" e2="DrugDDI.d125.s0.e4" id="DrugDDI.d125.s0.p3" interaction="false"/><pair e1="DrugDDI.d125.s0.e0" e2="DrugDDI.d125.s0.e5" id="DrugDDI.d125.s0.p4" interaction="false"/><pair e1="DrugDDI.d125.s0.e1" e2="DrugDDI.d125.s0.e2" id="DrugDDI.d125.s0.p5" interaction="false"/><pair e1="DrugDDI.d125.s0.e1" e2="DrugDDI.d125.s0.e3" id="DrugDDI.d125.s0.p6" interaction="false"/><pair e1="DrugDDI.d125.s0.e1" e2="DrugDDI.d125.s0.e4" id="DrugDDI.d125.s0.p7" interaction="false"/><pair e1="DrugDDI.d125.s0.e1" e2="DrugDDI.d125.s0.e5" id="DrugDDI.d125.s0.p8" interaction="false"/><pair e1="DrugDDI.d125.s0.e2" e2="DrugDDI.d125.s0.e3" id="DrugDDI.d125.s0.p9" interaction="false"/><pair e1="DrugDDI.d125.s0.e2" e2="DrugDDI.d125.s0.e4" id="DrugDDI.d125.s0.p10" interaction="false"/><pair e1="DrugDDI.d125.s0.e2" e2="DrugDDI.d125.s0.e5" id="DrugDDI.d125.s0.p11" interaction="false"/><pair e1="DrugDDI.d125.s0.e3" e2="DrugDDI.d125.s0.e4" id="DrugDDI.d125.s0.p12" interaction="false"/><pair e1="DrugDDI.d125.s0.e3" e2="DrugDDI.d125.s0.e5" id="DrugDDI.d125.s0.p13" interaction="false"/><pair e1="DrugDDI.d125.s0.e4" e2="DrugDDI.d125.s0.e5" id="DrugDDI.d125.s0.p14" interaction="false"/></sentence><sentence id="DrugDDI.d125.s1" origId="s1" text="Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when TAXOL was administered following cisplatin."><entity charOffset="68-78" id="DrugDDI.d125.s1.e0" origId="s1.p37" text="paclitaxel" type="drug"/><entity charOffset="115-120" id="DrugDDI.d125.s1.e1" origId="s1.p40" text="TAXOL" type="drug"/><entity charOffset="148-157" id="DrugDDI.d125.s1.e2" origId="s1.p44" text="cisplatin" type="drug"/><pair e1="DrugDDI.d125.s1.e0" e2="DrugDDI.d125.s1.e1" id="DrugDDI.d125.s1.p0" interaction="false"/><pair e1="DrugDDI.d125.s1.e0" e2="DrugDDI.d125.s1.e2" id="DrugDDI.d125.s1.p1" interaction="false"/><pair e1="DrugDDI.d125.s1.e1" e2="DrugDDI.d125.s1.e2" id="DrugDDI.d125.s1.p2" interaction="true"/></sentence><sentence id="DrugDDI.d125.s2" origId="s2" text="The metabolism of TAXOL is catalyzed by cytochrome P450 isoen-zymes CYP2C8 and CYP3A4."><entity charOffset="18-23" id="DrugDDI.d125.s2.e0" origId="s2.p46" text="TAXOL" type="drug"/><entity charOffset="40-55" id="DrugDDI.d125.s2.e1" origId="s2.p49" text="cytochrome P450" type="drug"/><entity charOffset="79-85" id="DrugDDI.d125.s2.e2" origId="s2.p51" text="CYP3A4" type="drug"/><pair e1="DrugDDI.d125.s2.e0" e2="DrugDDI.d125.s2.e1" id="DrugDDI.d125.s2.p0" interaction="true"/><pair e1="DrugDDI.d125.s2.e0" e2="DrugDDI.d125.s2.e2" id="DrugDDI.d125.s2.p1" interaction="true"/><pair e1="DrugDDI.d125.s2.e1" e2="DrugDDI.d125.s2.e2" id="DrugDDI.d125.s2.p2" interaction="false"/></sentence><sentence id="DrugDDI.d125.s3" origId="s3" text="In the absence of formal clinical drug interaction studies, caution should be exercised when administering TAXOL concomitantly with known substrates or inhibitors of the cytochrome P450 isoenzymes CYP2C8 and CYP3A4."><entity charOffset="107-112" id="DrugDDI.d125.s3.e0" origId="s3.p59" text="TAXOL" type="drug"/><entity charOffset="170-185" id="DrugDDI.d125.s3.e1" origId="s3.p63" text="cytochrome P450" type="drug"/><entity charOffset="208-214" id="DrugDDI.d125.s3.e2" origId="s3.p65" text="CYP3A4" type="drug"/><pair e1="DrugDDI.d125.s3.e0" e2="DrugDDI.d125.s3.e1" id="DrugDDI.d125.s3.p0" interaction="true"/><pair e1="DrugDDI.d125.s3.e0" e2="DrugDDI.d125.s3.e2" id="DrugDDI.d125.s3.p1" interaction="true"/><pair e1="DrugDDI.d125.s3.e1" e2="DrugDDI.d125.s3.e2" id="DrugDDI.d125.s3.p2" interaction="false"/><negationtags>In the &lt;xcope&gt;&lt;cue&gt;absence&lt;/cue&gt; of formal clinical drug interaction studies, caution should be exercised &lt;/xcope&gt; when administering TAXOL concomitantly with known substrates or inhibitors of the cytochrome P450 isoenzymes CYP2C8 and CYP3A4.</negationtags></sentence><sentence id="DrugDDI.d125.s4" origId="s4" text="Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (ritonavir, saquinavir, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials."><entity charOffset="31-36" id="DrugDDI.d125.s4.e0" origId="s4.p67" text="TAXOL" type="drug"/><entity charOffset="53-59" id="DrugDDI.d125.s4.e1" origId="s4.p69" text="CYP3A4" type="drug"/><entity charOffset="65-84" id="DrugDDI.d125.s4.e2" origId="s4.p71" text="protease inhibitors" type="drug"/><entity charOffset="86-95" id="DrugDDI.d125.s4.e3" origId="s4.p73" text="ritonavir" type="drug"/><entity charOffset="97-107" id="DrugDDI.d125.s4.e4" origId="s4.p74" text="saquinavir" type="drug"/><entity charOffset="109-118" id="DrugDDI.d125.s4.e5" origId="s4.p75" text="indinavir" type="drug"/><entity charOffset="124-134" id="DrugDDI.d125.s4.e6" origId="s4.p77" text="nelfinavir" type="drug"/><entity charOffset="179-185" id="DrugDDI.d125.s4.e7" origId="s4.p85" text="CYP3A4" type="drug"/><pair e1="DrugDDI.d125.s4.e0" e2="DrugDDI.d125.s4.e1" id="DrugDDI.d125.s4.p0" interaction="false"/><pair e1="DrugDDI.d125.s4.e0" e2="DrugDDI.d125.s4.e2" id="DrugDDI.d125.s4.p1" interaction="false"/><pair e1="DrugDDI.d125.s4.e0" e2="DrugDDI.d125.s4.e3" id="DrugDDI.d125.s4.p2" interaction="false"/><pair e1="DrugDDI.d125.s4.e0" e2="DrugDDI.d125.s4.e4" id="DrugDDI.d125.s4.p3" interaction="false"/><pair e1="DrugDDI.d125.s4.e0" e2="DrugDDI.d125.s4.e5" id="DrugDDI.d125.s4.p4" interaction="false"/><pair e1="DrugDDI.d125.s4.e0" e2="DrugDDI.d125.s4.e6" id="DrugDDI.d125.s4.p5" interaction="false"/><pair e1="DrugDDI.d125.s4.e0" e2="DrugDDI.d125.s4.e7" id="DrugDDI.d125.s4.p6" interaction="false"/><pair e1="DrugDDI.d125.s4.e1" e2="DrugDDI.d125.s4.e2" id="DrugDDI.d125.s4.p7" interaction="false"/><pair e1="DrugDDI.d125.s4.e1" e2="DrugDDI.d125.s4.e3" id="DrugDDI.d125.s4.p8" interaction="false"/><pair e1="DrugDDI.d125.s4.e1" e2="DrugDDI.d125.s4.e4" id="DrugDDI.d125.s4.p9" interaction="false"/><pair e1="DrugDDI.d125.s4.e1" e2="DrugDDI.d125.s4.e5" id="DrugDDI.d125.s4.p10" interaction="false"/><pair e1="DrugDDI.d125.s4.e1" e2="DrugDDI.d125.s4.e6" id="DrugDDI.d125.s4.p11" interaction="false"/><pair e1="DrugDDI.d125.s4.e1" e2="DrugDDI.d125.s4.e7" id="DrugDDI.d125.s4.p12" interaction="false"/><pair e1="DrugDDI.d125.s4.e2" e2="DrugDDI.d125.s4.e3" id="DrugDDI.d125.s4.p13" interaction="false"/><pair e1="DrugDDI.d125.s4.e2" e2="DrugDDI.d125.s4.e4" id="DrugDDI.d125.s4.p14" interaction="false"/><pair e1="DrugDDI.d125.s4.e2" e2="DrugDDI.d125.s4.e5" id="DrugDDI.d125.s4.p15" interaction="false"/><pair e1="DrugDDI.d125.s4.e2" e2="DrugDDI.d125.s4.e6" id="DrugDDI.d125.s4.p16" interaction="false"/><pair e1="DrugDDI.d125.s4.e2" e2="DrugDDI.d125.s4.e7" id="DrugDDI.d125.s4.p17" interaction="false"/><pair e1="DrugDDI.d125.s4.e3" e2="DrugDDI.d125.s4.e4" id="DrugDDI.d125.s4.p18" interaction="false"/><pair e1="DrugDDI.d125.s4.e3" e2="DrugDDI.d125.s4.e5" id="DrugDDI.d125.s4.p19" interaction="false"/><pair e1="DrugDDI.d125.s4.e3" e2="DrugDDI.d125.s4.e6" id="DrugDDI.d125.s4.p20" interaction="false"/><pair e1="DrugDDI.d125.s4.e3" e2="DrugDDI.d125.s4.e7" id="DrugDDI.d125.s4.p21" interaction="false"/><pair e1="DrugDDI.d125.s4.e4" e2="DrugDDI.d125.s4.e5" id="DrugDDI.d125.s4.p22" interaction="false"/><pair e1="DrugDDI.d125.s4.e4" e2="DrugDDI.d125.s4.e6" id="DrugDDI.d125.s4.p23" interaction="false"/><pair e1="DrugDDI.d125.s4.e4" e2="DrugDDI.d125.s4.e7" id="DrugDDI.d125.s4.p24" interaction="false"/><pair e1="DrugDDI.d125.s4.e5" e2="DrugDDI.d125.s4.e6" id="DrugDDI.d125.s4.p25" interaction="false"/><pair e1="DrugDDI.d125.s4.e5" e2="DrugDDI.d125.s4.e7" id="DrugDDI.d125.s4.p26" interaction="false"/><pair e1="DrugDDI.d125.s4.e6" e2="DrugDDI.d125.s4.e7" id="DrugDDI.d125.s4.p27" interaction="false"/><negationtags>Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (ritonavir, saquinavir, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, &lt;xcope&gt;have &lt;cue&gt;not&lt;/cue&gt; been evaluated in clinical trials&lt;/xcope&gt;.</negationtags></sentence><sentence id="DrugDDI.d125.s5" origId="s5" text="Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination."><entity charOffset="56-67" id="DrugDDI.d125.s5.e0" origId="s5.p95" text="doxorubicin" type="drug"/><entity charOffset="77-94" id="DrugDDI.d125.s5.e1" origId="s5.p98" text="active metabolite" type="drug"/><entity charOffset="132-142" id="DrugDDI.d125.s5.e2" origId="s5.p104" text="paclitaxel" type="drug"/><entity charOffset="147-158" id="DrugDDI.d125.s5.e3" origId="s5.p106" text="doxorubicin" type="drug"/><pair e1="DrugDDI.d125.s5.e0" e2="DrugDDI.d125.s5.e1" id="DrugDDI.d125.s5.p0" interaction="false"/><pair e1="DrugDDI.d125.s5.e0" e2="DrugDDI.d125.s5.e2" id="DrugDDI.d125.s5.p1" interaction="false"/><pair e1="DrugDDI.d125.s5.e0" e2="DrugDDI.d125.s5.e3" id="DrugDDI.d125.s5.p2" interaction="false"/><pair e1="DrugDDI.d125.s5.e1" e2="DrugDDI.d125.s5.e2" id="DrugDDI.d125.s5.p3" interaction="false"/><pair e1="DrugDDI.d125.s5.e1" e2="DrugDDI.d125.s5.e3" id="DrugDDI.d125.s5.p4" interaction="false"/><pair e1="DrugDDI.d125.s5.e2" e2="DrugDDI.d125.s5.e3" id="DrugDDI.d125.s5.p5" interaction="true"/></sentence><sentence id="DrugDDI.d125.s6" origId="s6" text="Hematology: TAXOL therapy should not be administered to patients with baseline neutrophil counts of less than 1,500 cells/mm3."><entity charOffset="12-17" id="DrugDDI.d125.s6.e0" origId="s6.p112" text="TAXOL" type="drug"/></sentence><sentence id="DrugDDI.d125.s7" origId="s7" text="In order to monitor the occurrence of myelotoxicity, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving TAXOL."><entity charOffset="153-158" id="DrugDDI.d125.s7.e0" origId="s7.p135" text="TAXOL" type="drug"/></sentence><sentence id="DrugDDI.d125.s8" origId="s8" text="Patients should not be re-treated with subsequent cycles of TAXOL until neutrophils recover to a level  1500 cells/mm3 and platelets recover to a level  100,000 cells/mm3."><entity charOffset="60-65" id="DrugDDI.d125.s8.e0" origId="s8.p142" text="TAXOL" type="drug"/><negationtags>&lt;xcope&gt; Patients should &lt;cue&gt;not&lt;/cue&gt; be re-treated with subsequent cycles of TAXOL&lt;/xcope&gt; until neutrophils recover to a level 1500 cells/mm3 and platelets recover to a level 100,000 cells/mm3.</negationtags></sentence><sentence id="DrugDDI.d125.s9" origId="s9" text="In the case of severe neutropenia ( 500 cells/mm3 for seven days or more) during a course of TAXOL therapy, a 20% reduction in dose for subsequent courses of therapy is recommended."><entity charOffset="93-98" id="DrugDDI.d125.s9.e0" origId="s9.p162" text="TAXOL" type="drug"/></sentence><sentence id="DrugDDI.d125.s10" origId="s10" text="For patients with advanced HIV disease and poor-risk AIDS-related Kaposi?s sarcoma, TAXOL, at the recommended dose for this disease, can be initiated and repeated if the neutrophil count is at least 1000 cells/mm3."><entity charOffset="27-30" id="DrugDDI.d125.s10.e0" origId="s10.p170" text="HIV" type="drug"/><entity charOffset="84-89" id="DrugDDI.d125.s10.e1" origId="s10.p173" text="TAXOL" type="drug"/><pair e1="DrugDDI.d125.s10.e0" e2="DrugDDI.d125.s10.e1" id="DrugDDI.d125.s10.p0" interaction="false"/></sentence><sentence id="DrugDDI.d125.s11" origId="s11" text="Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor? EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL."><entity charOffset="131-142" id="DrugDDI.d125.s11.e0" origId="s11.p198" text="cyclosporin" type="drug"/><entity charOffset="173-183" id="DrugDDI.d125.s11.e1" origId="s11.p201" text="teniposide" type="drug"/><entity charOffset="238-243" id="DrugDDI.d125.s11.e2" origId="s11.p208" text="TAXOL" type="drug"/><pair e1="DrugDDI.d125.s11.e0" e2="DrugDDI.d125.s11.e1" id="DrugDDI.d125.s11.p0" interaction="false"/><pair e1="DrugDDI.d125.s11.e0" e2="DrugDDI.d125.s11.e2" id="DrugDDI.d125.s11.p1" interaction="true"/><pair e1="DrugDDI.d125.s11.e1" e2="DrugDDI.d125.s11.e2" id="DrugDDI.d125.s11.p2" interaction="true"/><negationtags>Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor? EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should &lt;xcope&gt;&lt;cue&gt;not&lt;/cue&gt; be treated with TAXOL&lt;/xcope&gt;.</negationtags></sentence><sentence id="DrugDDI.d125.s12" origId="s12" text="In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and H2 antagonists (such as cimetidine or ranitidine)."><entity charOffset="97-102" id="DrugDDI.d125.s12.e0" origId="s12.p215" text="TAXOL" type="drug"/><entity charOffset="131-146" id="DrugDDI.d125.s12.e1" origId="s12.p219" text="corticosteroids" type="drug"/><entity charOffset="156-169" id="DrugDDI.d125.s12.e2" origId="s12.p221" text="dexamethasone" type="drug"/><entity charOffset="172-178" id="DrugDDI.d125.s12.e3" origId="s12.p224" text="diphen" type="drug"/><entity charOffset="217-227" id="DrugDDI.d125.s12.e4" origId="s12.p228" text="cimetidine" type="drug"/><entity charOffset="231-241" id="DrugDDI.d125.s12.e5" origId="s12.p230" text="ranitidine" type="drug"/><pair e1="DrugDDI.d125.s12.e0" e2="DrugDDI.d125.s12.e1" id="DrugDDI.d125.s12.p0" interaction="false"/><pair e1="DrugDDI.d125.s12.e0" e2="DrugDDI.d125.s12.e2" id="DrugDDI.d125.s12.p1" interaction="false"/><pair e1="DrugDDI.d125.s12.e0" e2="DrugDDI.d125.s12.e3" id="DrugDDI.d125.s12.p2" interaction="false"/><pair e1="DrugDDI.d125.s12.e0" e2="DrugDDI.d125.s12.e4" id="DrugDDI.d125.s12.p3" interaction="false"/><pair e1="DrugDDI.d125.s12.e0" e2="DrugDDI.d125.s12.e5" id="DrugDDI.d125.s12.p4" interaction="false"/><pair e1="DrugDDI.d125.s12.e1" e2="DrugDDI.d125.s12.e2" id="DrugDDI.d125.s12.p5" interaction="false"/><pair e1="DrugDDI.d125.s12.e1" e2="DrugDDI.d125.s12.e3" id="DrugDDI.d125.s12.p6" interaction="false"/><pair e1="DrugDDI.d125.s12.e1" e2="DrugDDI.d125.s12.e4" id="DrugDDI.d125.s12.p7" interaction="false"/><pair e1="DrugDDI.d125.s12.e1" e2="DrugDDI.d125.s12.e5" id="DrugDDI.d125.s12.p8" interaction="false"/><pair e1="DrugDDI.d125.s12.e2" e2="DrugDDI.d125.s12.e3" id="DrugDDI.d125.s12.p9" interaction="false"/><pair e1="DrugDDI.d125.s12.e2" e2="DrugDDI.d125.s12.e4" id="DrugDDI.d125.s12.p10" interaction="false"/><pair e1="DrugDDI.d125.s12.e2" e2="DrugDDI.d125.s12.e5" id="DrugDDI.d125.s12.p11" interaction="false"/><pair e1="DrugDDI.d125.s12.e3" e2="DrugDDI.d125.s12.e4" id="DrugDDI.d125.s12.p12" interaction="false"/><pair e1="DrugDDI.d125.s12.e3" e2="DrugDDI.d125.s12.e5" id="DrugDDI.d125.s12.p13" interaction="false"/><pair e1="DrugDDI.d125.s12.e4" e2="DrugDDI.d125.s12.e5" id="DrugDDI.d125.s12.p14" interaction="false"/></sentence><sentence id="DrugDDI.d125.s13" origId="s13" text="Minor symptoms such as flushing, skin reactions, dyspnea, hypotension, or tachycardia do not require interruption of therapy."><negationtags>Minor symptoms such as flushing, skin reactions, dyspnea, hypotension, or tachycardia do &lt;xcope&gt;&lt;cue&gt;not&lt;/cue&gt; require interruption of therapy&lt;/xcope&gt;.</negationtags></sentence><sentence id="DrugDDI.d125.s14" origId="s14" text="However, severe reactions, such as hypotension requiring treatment, dyspnea requiring bronchodilators, angioedema, or generalized urticaria require immediate discontinuation of TAXOL and aggressive symptomatic therapy."><entity charOffset="86-101" id="DrugDDI.d125.s14.e0" origId="s14.p247" text="bronchodilators" type="drug"/><entity charOffset="177-182" id="DrugDDI.d125.s14.e1" origId="s14.p253" text="TAXOL" type="drug"/><pair e1="DrugDDI.d125.s14.e0" e2="DrugDDI.d125.s14.e1" id="DrugDDI.d125.s14.p0" interaction="false"/></sentence><sentence id="DrugDDI.d125.s15" origId="s15" text="Patients who have developed severe hypersensitivity reactions should not be rechallenged with TAXOL."><entity charOffset="94-99" id="DrugDDI.d125.s15.e0" origId="s15.p265" text="TAXOL" type="drug"/><negationtags>&lt;xcope&gt; Patients who have developed severe hypersensitivity reactions should &lt;cue&gt;not&lt;/cue&gt; be rechallenged&lt;/xcope&gt; with TAXOL.</negationtags></sentence><sentence id="DrugDDI.d125.s16" origId="s16" text="Cardiovascular: Hypotension, bradycardia, and hypertension have been observed during administration of TAXOL, but generally do not require treatment."><entity charOffset="103-108" id="DrugDDI.d125.s16.e0" origId="s16.p276" text="TAXOL" type="drug"/><negationtags>Cardiovascular: Hypotension, bradycardia, and hypertension have been observed during administration of TAXOL, but generally do &lt;xcope&gt;&lt;cue&gt;not&lt;/cue&gt; require treatment&lt;/xcope&gt;.</negationtags></sentence><sentence id="DrugDDI.d125.s17" origId="s17" text="Occasionally TAXOL infusions must be interrupted or discontinued because of initial or recurrent hypertension."><entity charOffset="13-18" id="DrugDDI.d125.s17.e0" origId="s17.p283" text="TAXOL" type="drug"/></sentence><sentence id="DrugDDI.d125.s18" origId="s18" text="Frequent vital sign monitoring, particularly during the first hour of TAXOL infusion, is recommended."><entity charOffset="70-75" id="DrugDDI.d125.s18.e0" origId="s18.p295" text="TAXOL" type="drug"/></sentence><sentence id="DrugDDI.d125.s19" origId="s19" text="Continuous cardiac monitoring is not required except for patients with serious conduction abnormalities."><negationtags>Continuous cardiac monitoring is &lt;xcope&gt;&lt;cue&gt;not&lt;/cue&gt; required except for patients with serious conduction abnormalities&lt;/xcope&gt;.</negationtags></sentence><sentence id="DrugDDI.d125.s20" origId="s20" text="Nervous System: Although the occurrence of peripheral neuropathy is frequent, the development of severe symptomatology is unusual and requires a dose reduction of 20% for all subsequentcourses of TAXOL."><entity charOffset="196-201" id="DrugDDI.d125.s20.e0" origId="s20.p320" text="TAXOL" type="drug"/></sentence><sentence id="DrugDDI.d125.s21" origId="s21" text="TAXOL contains dehydrated alcohol USP, 396 mg/mL;"><entity charOffset="0-5" id="DrugDDI.d125.s21.e0" origId="s21.p321" text="TAXOL" type="drug"/><entity charOffset="15-38" id="DrugDDI.d125.s21.e1" origId="s21.p323" text="dehydrated alcohol USP" type="drug"/><pair e1="DrugDDI.d125.s21.e0" e2="DrugDDI.d125.s21.e1" id="DrugDDI.d125.s21.p0" interaction="false"/></sentence><sentence id="DrugDDI.d125.s22" origId="s22" text="consideration should be given to possible CNS and other effects of alcohol."><entity charOffset="67-74" id="DrugDDI.d125.s22.e0" origId="s22.p334" text="alcohol" type="drug"/></sentence><sentence id="DrugDDI.d125.s23" origId="s23" text="Hepatic: There is limited evidence that the myelotoxicity of TAXOL may be exacerbated in patients with serum total bilirubin  2 times ULN."><entity charOffset="61-66" id="DrugDDI.d125.s23.e0" origId="s23.p342" text="TAXOL" type="drug"/></sentence><sentence id="DrugDDI.d125.s24" origId="s24" text="Extreme caution should be exercised when administering TAXOL to such patients, with dose reduction as recommended in DOSAGE AND ADMINISTRATION, Table 17."><entity charOffset="55-60" id="DrugDDI.d125.s24.e0" origId="s24.p354" text="TAXOL" type="drug"/></sentence><sentence id="DrugDDI.d125.s25" origId="s25" text="InjectionSite Reaction: Injection site reactions, including reactions secondary to extravasation, were usually mild and consisted of erythema, tenderness, skin discoloration, or swelling at the injection site."/><sentence id="DrugDDI.d125.s26" origId="s26" text="These reactions have been observed more frequently with the 24-hour infusion than with the 3-hour infusion."/><sentence id="DrugDDI.d125.s27" origId="s27" text="Recurrence of skin reactions at a site of previous extravasation following administration of TAXOL at a different site, ie, recall, has been reported rarely."><entity charOffset="93-98" id="DrugDDI.d125.s27.e0" origId="s27.p393" text="TAXOL" type="drug"/></sentence><sentence id="DrugDDI.d125.s28" origId="s28" text="Rare reports of more severe events such as phlebitis, cellulitis, induration, skin exfoliation, necrosis, and fibrosis have been received as part of the continuing surveillance of TAXOL safety."><entity charOffset="180-185" id="DrugDDI.d125.s28.e0" origId="s28.p417" text="TAXOL" type="drug"/></sentence><sentence id="DrugDDI.d125.s29" origId="s29" text="In some cases the onset of the injection site reaction either occurred during a prolonged infusion or was delayed by a week to ten days."/><sentence id="DrugDDI.d125.s30" origId="s30" text="A specific treatment for extravasation reactions is unknown at this time."/><sentence id="DrugDDI.d125.s31" origId="s31" text="Given the possibility of extravasation, it is advisable to closely monitor the infusion site for possible infiltration during drug administration."/></document>